122 related articles for article (PubMed ID: 2979058)
1. Radioiodinated monoclonal antibodies in the imaging and treatment of human renal cell carcinoma xenografts in nude mice.
Vessella RL; Lange PH; Palme DF; Chiou RK; Elson MK; Wessels BW
Targeted Diagn Ther; 1988; 1():245-82. PubMed ID: 2979058
[No Abstract] [Full Text] [Related]
2. Site-specific modification of monoclonal antibodies. Studies of 111indium-labeled antibodies using nude mouse xenograft systems.
Alvarez VL; Lopes AD; Lee C; Coughlin DJ; Rodwell JD; McKearn TJ
Targeted Diagn Ther; 1988; 1():283-315. PubMed ID: 2979060
[No Abstract] [Full Text] [Related]
3. The effect of antibody protein dose of anti-renal cell carcinoma monoclonal antibodies in nude mice with renal cell carcinoma xenografts.
Kranenborg MH; Boerman OC; de Weijert MC; Oosterwijk-Wakka JC; Corstens FH; Oosterwijk E
Cancer; 1997 Dec; 80(12 Suppl):2390-7. PubMed ID: 9406688
[TBL] [Abstract][Full Text] [Related]
4. The impact of tumor size on the efficacy of monoclonal antibody-targeted radiotherapy: studies using a nude mouse model with human renal cell carcinoma xenografts.
Chiou RK
J Urol; 1991 Jul; 146(1):232-7. PubMed ID: 2056596
[TBL] [Abstract][Full Text] [Related]
5. Radiobiological comparison of external beam irradiation and radioimmunotherapy in renal cell carcinoma xenografts.
Wessels BW; Vessella RL; Palme DF; Berkopec JM; Smith GK; Bradley EW
Int J Radiat Oncol Biol Phys; 1989 Dec; 17(6):1257-63. PubMed ID: 2599909
[TBL] [Abstract][Full Text] [Related]
6. Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma.
Divgi CR; Bander NH; Scott AM; O'Donoghue JA; Sgouros G; Welt S; Finn RD; Morrissey F; Capitelli P; Williams JM; Deland D; Nakhre A; Oosterwijk E; Gulec S; Graham MC; Larson SM; Old LJ
Clin Cancer Res; 1998 Nov; 4(11):2729-39. PubMed ID: 9829736
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic model of iodine-131-G250 antibody in renal cell carcinoma patients.
Loh A; Sgouros G; O'Donoghue JA; Deland D; Puri D; Capitelli P; Humm JL; Larson SM; Old LJ; Divgi CR
J Nucl Med; 1998 Mar; 39(3):484-9. PubMed ID: 9529296
[TBL] [Abstract][Full Text] [Related]
8. Phase I radioimmunotherapy of metastatic renal cell carcinoma with 131I-labeled chimeric monoclonal antibody G250.
Steffens MG; Boerman OC; de Mulder PH; Oyen WJ; Buijs WC; Witjes JA; van den Broek WJ; Oosterwijk-Wakka JC; Debruyne FM; Corstens FH; Oosterwijk E
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3268s-3274s. PubMed ID: 10541374
[TBL] [Abstract][Full Text] [Related]
9. Radioimmunoscintigraphy and radioimmunotherapy of renal cell carcinoma xenografts.
Vessella RL; Alvarez V; Chiou RK; Rodwell J; Elson M; Palme D; Shafer R; Lange P
NCI Monogr; 1987; (3):159-67. PubMed ID: 3821914
[TBL] [Abstract][Full Text] [Related]
10. Monoclonal antibodies in human renal cell carcinoma and their use in radioimmune localization and therapy of tumor xenografts.
Lange PH; Vessella RL; Chiou RK; Elson MK; Moon TD; Palme D; Shafer RK
Surgery; 1985 Aug; 98(2):143-50. PubMed ID: 4023915
[TBL] [Abstract][Full Text] [Related]
11. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
Brouwers AH; van Eerd JE; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
J Nucl Med; 2004 Feb; 45(2):327-37. PubMed ID: 14960657
[TBL] [Abstract][Full Text] [Related]
12. Positron emission tomography (PET), immuno-PET and radioimmunotherapy in renal cell carcinoma: a developing diagnostic and therapeutic relationship.
Lawrentschuk N; Davis ID; Bolton DM; Scott AM
BJU Int; 2006 May; 97(5):916-22. PubMed ID: 16643471
[No Abstract] [Full Text] [Related]
13. Dosimetry and pharmacokinetics of monoclonal antibody A6H with human renal cell carcinoma xenografts: single dose study.
Palme DF; Berkopec JM; Wessels BW; Elson MK; Lange PH; Vessella RL
Int J Rad Appl Instrum B; 1991; 18(5):527-37. PubMed ID: 1917523
[TBL] [Abstract][Full Text] [Related]
14. Radioimmunotherapy for pancreatic carcinoma using (131)I-labeled monoclonal antibody Nd2 in xenografted nude mice.
Inui A; Chung YS; Sawada T; Kondo Y; Ho JJ; Kim YS; Sowa M
Jpn J Cancer Res; 1996 Sep; 87(9):977-84. PubMed ID: 8878462
[TBL] [Abstract][Full Text] [Related]
15. Biodistribution and radioimmunoscintigraphy studies of renal cell carcinoma using tumor-preferential monoclonal antibodies and F(ab')2 fragments.
Chiou RK
J Urol; 1989 Dec; 142(6):1584-8. PubMed ID: 2585642
[TBL] [Abstract][Full Text] [Related]
16. Imaging and therapy with monoclonal antibodies in non-hematopoietic tumors.
Mach JP; Pèlegrin A; Buchegger F
Curr Opin Immunol; 1991 Oct; 3(5):685-93. PubMed ID: 1755986
[TBL] [Abstract][Full Text] [Related]
17. Experimental model for radioimmunotherapy of human ovarian carcinoma with I-131-labeled monoclonal antibody OC 125.
Senekowitsch R; Schmid P; Möllenstädt S; Kriegel H; Pabst HW
Strahlenther Onkol; 1989 Jul; 165(7):564-6. PubMed ID: 2749501
[No Abstract] [Full Text] [Related]
18. Fractionated radioimmunotherapy of human colon carcinoma xenografts with 131I-labeled monoclonal antibody CC49.
Buchsbaum D; Khazaeli MB; Liu T; Bright S; Richardson K; Jones M; Meredith R
Cancer Res; 1995 Dec; 55(23 Suppl):5881s-5887s. PubMed ID: 7493364
[TBL] [Abstract][Full Text] [Related]
19. Optimizing lutetium 177-anti-carbonic anhydrase IX radioimmunotherapy in an intraperitoneal clear cell renal cell carcinoma xenograft model.
Muselaers CH; Oosterwijk E; Bos DL; Oyen WJ; Mulders PF; Boerman OC
Mol Imaging; 2014; 13():1-7. PubMed ID: 24824962
[TBL] [Abstract][Full Text] [Related]
20. Radioimmunodetection of a transplantable human bladder carcinoma in a nude mouse.
Gross MD; Skinner RW; Grossman HB
Invest Radiol; 1984; 19(6):530-4. PubMed ID: 6511260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
